Besides providing new therapeutic strategies to target KRAS-mutant cancer, sotorasib and adagrasib also provide a potential therapeutic rational to overcome KRAS secondary mutations mediating resistance to other therapies in other oncogenic driven NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.